Comparison of studies
| View/Edit | Study Name | Start Date | Study Types | Experimental Models | Model Types | Disease(s) | Data Points | Data Points (omic) | Images | Videos | Plate Maps | Plate Reader Files | Supporting Data Files | Description | Reproducibility Status | Center | Data Entry | Review | Sign Off Date | Data Provider | ID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| View/Edit | Heart_Tier1_UCB_2D_a | 2019-05-30 | TOX-CC | Cardiac Static [TAMU 384w] | Static-2D | -No Diseases- | 1,248 | 0 | 96 | 20 | 0 | 0 | 1 | This study is a repeat of “Heart_Tier1_UCB_2D”. In the original study, only phase contrast video capture was performed, due to issues with the calcium-sensitive dye. In this study, the same treaments/exposures were repeated, capturing both the phase contrast videos for motion analysis, as well as the calcium flux data. This tier of testing was a 2D companion to the 3D heart chip study to measure the effects of drugs on cardiomyocytes seeded within the UC-Berkeley chips. In this study, 160 wells were seeded with iPSC-derived cardiomyocytes provided by UC-Berkeley, as well as supporting fibroblasts (iPS-stromal cells) in a 384-well cell culture plate. Cells were cultured over 4 days in the plate prior to testing with reference compounds. Cultures were treated with either a media control, vehicle (0.1% DMSO), cisapride, verapamil, or isoproterenol for a 25 minute exposure at concentrations of 1, 10, 100, 1000, and 10000nM (n=10 for all controls and treatments). After each exposure, phase contrast images were captured (10FPS), and analyzed using the MotionGUI script in Matlab (provided by UC-Berkeley). The outputs of this program were beat rate (BPM), time interval (s, duration between contraction and relaxation), contraction velocity (px/s), and relaxation velocity (px/s). Additionally, a calcium sensitive dye was added to capture calcium flux at baseline and after treatment. | TEX-VAL | Courtney Sakolish | 4 | 2019-10-01 | Rusyn_TAMU | 336 | |
| View/Edit | Heart_Tier2_UCB_3D | 2018-05-25 | TOX | Cardiac MPS | Fluidic-3D | -No Diseases- | 4,104 | 0 | 511 | 58 | 0 | 0 | 2 | This tier of testing was part of the 3D heart chip study to measure the effects of drugs on cardiomyocytes seeded within the UC-Berkeley chips. In this study, 55 chips were seeded with iPSC-derived cardiomyocytes provided by UC-Berkeley as well as supporting fibroblasts (iPS-stromal cells) in a central growth chamber. Cells were cultured over 5 days in the chip prior to testing with reference compounds. Cultures were treated with either vehicle (n=12, 0.1% DMSO), atenolol (0.01µM, n=4; 0.1µM, n=4; 1µM, n=3; 10µM, n=3), sorafenib (0.1µM, n=4; 1µM, n=4; 10µM, n=4; 100µM, n=3) or carbamazepine (0.1, 1, 10, 100µM, n=4 each) over a 1 week period. At each timepoint (baseline, 5 hours, and daily for days 1-7), phase contrast images were captured (10FPS), and analyzed using the MotionGUI script in Matlab (provided by UC-Berkeley). The outputs of this program were beat rate (BPM), time interval (s, duration between contraction and relaxation), contraction velocity (px/s), and relaxation velocity (px/s). Immunohistochemistry was difficult in this chip, so images are displayed as phase contrast only. | TEX-VAL | Michael Castiglione | 4 | 2019-09-27 | Rusyn_TAMU | 217 |